In our study, approximately 90% of cases contained a sufficient number of cancer cells to reach an average margin of error below 0.1 for both the HER2/CEP17 ratio and the average of HER2 copy number per cell, all achieved within a clinically acceptable analysis time of under 4 min. The gene discussed is ERBB2; the disease is cancer.